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Abstract
Background: The aberrant expression of sperm-associated antigen 9 (SPAG9) is associated with numerous cancers,
including hepatocellular carcinoma (HCC). The exploration of molecules and mechanisms regulating SPAG9 expression
may provide new options for HCC therapy.
Methods: MiRNA target prediction programs were used to explore SPAG9-targeted miRNAs. SPAG9 and miR-141
expression were detected in HCC tissues and cell lines by Western blot and real-time PCR. Dual-luciferase reporter assay
was utilized to validate SPAG9 as a direct target gene of miR-141. Cell proliferation, invasion, and migration assays were
used to determine whether miR-141-mediated regulation of SPAG9 could affect HCC progression.
Results: An inverse correlation was observed between SPAG9 and miR-141 expression in HCC tissues and cell lines.
Dual-luciferase reporter assay further showed that SPAG9 was a direct target gene of miR-141. The ectopic expression
of miR-141 could markedly suppress SPAG9 expression in HCC cells. MiR-141 overexpression also resulted in
significantly reduced cell proliferation, invasion, and migration, and imitation of the SPAG9 knockdown effects on HCC
cells. Furthermore, SPAG9 restoration in miR-141-expressing cells sufficiently attenuated the tumor-suppressive effects
of miR-141. Finally, JNK activity was found to be reduced by miR-141 overexpression the same way as by SPAG9
silencing. The overexpression of SPAG9 lacking its 3′-UTR significantly restored JNK activity and its downstream genes
in miR-141-transfected HCC cells.
Conclusion: MiR-141 suppression may cause aberrant expression of SPAG9 and promote HCC tumorigenesis via JNK
pathway.
Keywords: SPAG9, HCC, miR-141, JNK
Background
Hepatocellular carcinoma (HCC) is the third cause of
cancer-related mortality in the world [1]. Like other can-
cers, HCC is the result of a complex process associated
with various genetic and epigenetic changes acting
through etiology-specific pathways [2]. However, the
complicated molecular pathogenesis of HCC remains
poorly understood, and the long-term survival rate con-
tinues to be low over the past two decades, despite exist-
ing strategies for HCC treatment. Therefore, further
uncovering the molecular mechanisms of HCC and ex-
ploring new therapeutic targets to improve HCC treat-
ment are very important.
Sperm-associated antigen 9 (SPAG9), which is a new
member of the cancer testis (CT) antigen family, was in-
volved in a c-Jun NH2-terminal kinase (JNK) signaling
pathway [3, 4]. Several studies have reported an associ-
ation of aberrant SPAG9 expressions in various types of
human cancers including breast, thyroid, cervical, and
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colon carcinoma [5–8]. The down-regulation of SPAG9
by siRNA approach could also inhibit tumor cell prolif-
eration and invasion [9, 10]. Recently, SPAG9 overex-
pression was identified to be correlated with poor
prognosis and tumor progression in human HCC [11].
However, the underlying mechanism causing SPAG9
overexpression in HCC remains unclear.
MicroRNAs (miRNAs) are small non-coding RNAs
that can cause mRNA degradation or translation inhib-
ition by interacting with the 3′-untranslated region (3′-
UTR) of the target gene mRNA [12–14]. Accumulated
evidences have shown that miRNAs play crucial roles in
HCC development through regulating the expression of
oncogenes or tumor suppressor genes [15, 16]. An aber-
rant expression of miRNAs such as miR-122, miR-184,
miR-106b, miR-219, miR-31, and miR-362-5p has been
reported to regulate tumor cell growth, apoptosis, migra-
tion, and invasion by targeting proteins involved in those
cellular pathways [17–22]. However, certain miRNA,
which can target and regulate the expression of SPAG9,
has not been identified.
In the present study, we used miRNA target prediction
programs to explore SPAG9-targeted miRNAs in hepa-
tocarcinogenesis and identified miR-141 as an endogen-
ous regulator of SPAG9 in HCC. MiR-141-mediated
SPAG9 regulation was also found to play important roles
in HCC cells growth, invasion, and migration. The data
in the present study suggest that suppression of miR-141
may cause an aberrant overexpression of SPAG9 and
that miR-141-mediated SPAG9 regulation may be a po-
tential strategy for HCC therapy.
Methods
Patients and clinical tissue specimens
Matched fresh HCC specimens and non-tumorous liver
samples were obtained from 10 clinically confirmed
HCC patients during hepatic resection at the First Affili-
ated Hospital of Zhejiang University. Samples were ei-
ther immediately snap-frozen in liquid nitrogen. The
hospital’s committee of ethics approved this study, and
informed consent was obtained from all patients.
Cell lines and cell culture
Human HCC cell lines (HepG2, Huh7, LM3 and
Hep3B), the human immortalized liver cell line HL-
7702, and the human embryonic kidney cell line
HEK293T were purchased from ATCC (American type
culture collection). These cells were maintained in their
complete growth medium according to the culture
method.
Isolation and detection of miRNA
Total RNA enriched with miRNAs was isolated from
HCC samples or HCC cells by using miRVana miRNA
isolation kit. Then real-time PCR analysis was performed
to examine miR-141 expression according to the manu-
facturer’s instructions (Ambion Diagnostics, TX). Data
are normalized over the average CT value of U6, and
2-ΔΔCT method was used to determine relative
miRNA expression.
Western blotting
HCC samples or HCC cells were lysed with RIPA pep-
tide lysis buffer (Beyotime Biotechnology, Jiangsu,
China) containing 1 % protease inhibitors (Pierce) and
Western blotting analysis were performed according to
standard procedures. Primary antibodies were used as
follows: anti-SPAG9 (1:1000, Abcam), anti-JNK, anti-p-
JNK, anti-c-Jun, and anti-MMP9 (1:2000, Abcam) and
anti-GAPDH (1:3000, Huabio). Protein bands were de-
veloped using the Enhanced Chemiluminescence (ECL)
system and were visualized and quantified by using the
ChemiScope Western Blot Imaging System (Clinx
Science Instruments Co., Ltd).
siRNA, miRNA and plasmid transfection
SiRNA against SPAG9 and scrambled siRNA were pur-
chased from RiboBio, mirVana™ negative control and
mirVana™ miR-141 mimics were purchased from Life
Technologies Inc, and SPAG9 overexpression plasmid
were constructed by Genechem. SiRNA and plasmid
transfection was carried out using lipofectamine™ 2000
(Invitrogen), miRNA transfection was carried out using
lipofectamine™ RNAiMAX (Invitrogen) according to the
manufacturer’s instructions. At 24 h after transfection,
the effects of gene silencing and miR-141 expression
were respectively measured by western blot analysis and
real-time PCR analysis.
Dual-luciferase assay
The 3′-UTR of SPAG9 containing the potential binding
sites of miR-141 was amplified using the following
primers: 5′- GGCGGCTCGAGAAAATCCGTTCTAC
CATAAC -3′, and 5′- AATGCGGCCGCAACTCAAT
CAACATCACCAT -3′. The PCR products were inserted
into pmiR-RB-REPORT™ vector within XhoI/NotI
restriction sites. Mutation was performed using a fast
mutation kit (NEB, Canada). HEK293T cells were co-
transfected with wild-type or mutant 3′-UTR of
SPAG9 and miR-141 or the control mimics. After
48 h, the cells were lysed, and the firefly and Renilla
luciferase activities were measured with the Dual-
Luciferase Reporter Assay System (Promega). The re-
sults are presented as the ratio of Renilla luciferase
activity to firefly luciferase activity.
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Cell proliferation assay
At 24 h after transfection with SPAG9 siRNA or miR-
141 mimics, HCC cells were plated in 96-well plates at
approximately 5,000 cells per well and maintained in
culture medium for 72 h. Cell proliferation was deter-
mined by methylthiazolyldiphenyl-tetrazolium bromide
(MTT) assay (Sigma).
Wound-healing assay
At 24 h after transfection, HCC cells were plated in 6-
well plates at approximately 1 × 106 cells per well. At
100 % confluency, cells were scratched with a 200-uL fil-
ter tip to create an artificial wound. After wounding, the
medium was changed to fresh serum free medium to re-
move cellular debris. Serial images were obtained at 0,
24 and 48 h.
Cell invasion assays
Cell invasion was assessed using the Matrigel Invasion
Chamber (BD Biosciences). Cells (1 × 105) were seeded
on transwell chambers with Matrigel in serumfree
medium. Medium containing 10 % FBS in the lower
chamber served as the chemo-attractant. The invasive
cells that attached to the lower surface of the membrane
insert were fixed with 4 % paraformaldehyde, stained
with 1 % crystal violet, and counted. Each experiment
was carried out in triplicate in 3 independent experi-
ments to ensure consistency.
RNA isolation and real-time PCR analysis
Total RNA was isolated from HCC cells with TRIzol
(Invitrogen), real-time PCR was performed on ABI 7900
system (Applied Biosystems) using SYBR Premix EX
TaqTM II kit (Takara) to examine the expression of
MMP9 and c-Jun, GAPDH was used as internal control.
The 2-ΔΔCT method was used to determine relative
mRNA expression.
Statistical analysis
Differences between groups were analyzed using conven-
tional Student’s t test or ANOVA. Each experiment was
repeated at least three times, and the data are presented
as mean ± SD. A P-value of 0.05 or less was considered
as statistically significant.
Results
SPAG9 expression level is inversely correlated with
miR-141 in HCC
By using three publicly available algorithms (TargetScan,
miRanda, and PicTar), miR-141 was identified as a can-
didate miRNA that could target SPAG9. As shown in
Fig. 1a, miR-141 has potential target sites in the 3′-UTR
of the SPAG9 mRNA sequence. Moreover, the miR-141
binding sequences in the SPAG9 3′-UTR are highly con-
served across species.
We then examined the expression levels of miR-141
and SPAG9 in 10 randomly selected HCC tissues paired
to adjacent non-cancerous liver tissues. As we expected,
9 out of 10 HCCs (90 %) had increased SPAG9 expres-
sion as compared with corresponding non-cancerous
hepatic tissues (Fig. 1b); whereas, the expression level of
miR-141 was decreased in these 9 HCC tissues as com-
pared with corresponding non-cancerous tissues (Fig. 1c).
Furthermore, the miR-141 and SPAG9 expressions were
observed in four human HCC cell lines (HepG2, Huh7,
LM3, and Hep3B) and an immortalized liver cell line
HL-7702. Consistent with the data obtained from HCC
tissues, the expression patterns of SPAG9 were also in-
versely correlated with those of miR-141 in cell lines
(Fig. 1d and e).
SPAG9 is the direct downstream target of miR-141
To determine whether SPAG9 was a direct target of
miR-141 in HCC, we cloned 728 bp fragments of the hu-
man SPAG9 3′-UTR mRNA containing the putative
miRNA-binding site into the pmiR-RB-REPORT™ vector
(Fig. 2a) and transfected this constructed vector
(SPAG9-WT) into HEK293T cells along with miR-141
mimics, or a non-target control miRNA (NC). Com-
pared with miR-NC, miR-141 induced a significant de-
crease in the normalized luciferase activity of the vector
containing the putative miRNA-binding site. In addition,
the mutation of the miR-141-responsive elements in the
binding site of SPAG9 3′-UTR (SPAG9-Mut) resulted in
an abrogation of the inhibitory effects of miR-141
(Fig. 2b).
The correlation between miR-141 and SPAG9 was fur-
ther examined by evaluating the expression of SPAG9 in
the human HCC cell line Huh7 and LM3 after the over-
expression of miR-141. As anticipated, the overexpres-
sion of miR-141 by transfection with miR-141 mimics
significantly reduced SPAG9 protein levels in Huh7 and
LM3 cells (Fig. 2c and d). These data strongly suggest
that SPAG9 is a direct target of miR-141. The aberrant
overexpression of SPAG9 in HCC may be caused by the
reduced expression of miR-141.
MiR-141-mediated downregulation of SPAG9 inhibits HCC
cell growth, migration, and invasion
The above-mentioned results prompted us to further ex-
plore the functional relationship between miR-141 and
SPAG9. MTT assay manifested that the downregulation
of SPAG9 by transfection with SPAG9 siRNA in Huh7
and LM3 cells resulted in a significant suppression of
cell proliferation (Fig. 3b). Likewise, a substantial reduc-
tion of cell proliferation was observed in miR-141
mimic-transfected cells (Fig. 3b). In addition, wound-
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healing and transwell assays showed that Huh7 cells
transfected with SPAG9 siRNA or miR-141 mimics
displayed reduced migratory and invasive activity as
compared with control siRNA (si-Ctrl) or miR-NC
transfected cells (Fig. 3c-f ).
Furthermore, to determine whether miR-141 re-
presses cell proliferation and metastasis by decreasing
SPAG9 level, we transduced either a control vector or a
SPAG9 overexpression plasmid into HCC cells com-
bined with miR-141 transfection. We found that the
overexpression of SPAG9 attenuated the inhibitory
effects of miR-141 mimics on HCC cell proliferation
(Fig. 4a). Wound-healing and transwell assay also
showed that the restoration of SPAG9 reversed the in-
hibitory effects of miR-141 mimics on HCC cell migra-
tion and invasion, respectively (Fig. 4b-e).
Overall, these results indicate that miR-141 might
modulate cell proliferation and metastasis by targeting
SPAG9.
MiR-141 regulates JNK signaling pathway via SPAG9 in
HCC cells
SPAG9 was reported to be involved in JNK signaling ac-
tivation [3], which is closely related to the occurrence
and development of HCC. To provide further mechanis-
tic insight into the role of miR-141 and SPAG9 in HCC
progression, we evaluated the effect of miR-141 on JNK
activation. We found that JNK and p-JNK decreased in
Huh7 cells after the transfection with miR-141 mimics
or SPAG9 siRNA (Fig. 5a). To further determine if miR-
141 repressed the JNK activity via SPAG9, we trans-
fected miR-141 combined with SPAG9 overexpression in
Fig. 1 SPAG9 expression is inversely correlated with miR-141 level in HCC. a The location of target sites of miR-141 in the SPAG9 3′-UTR is shown.
b The protein level of SPAG9 in 10 paired HCCs (T) and non-cancerous hepatic tissues (N) were determined by Western blot analysis. (C and D)
The expression levels of miR-141 were performed by real time-PCR in HCC tissues (c) and cell lines (d). e Western blot analysis of SPAG9 expression
levels in human liver cell lines. Data are presented as the mean ± S.D. (*P < 0.05, n = 3)
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HCC cells. Figure 5b shows that the SPAG9 overexpres-
sion significantly restored JNK activity in miR-141-
transfected Huh7 cells. We also quantified the JNK
downstream target gene levels after miR-141 overexpres-
sion, such as MMP9 and c-Jun. We discovered that the
upregulation of miR-141 dramatically decreased c-Jun
and MMP9 expression, while the restoration of SPAG9
expression reversed the effects of miR-141 on genes ex-
pression (Fig. 5c and d). Overall, these data suggest that
miR-141 inhibits the JNK signaling pathway via SPAG9.
Discussion
SPAG9 is involved in the JNK-signaling module and play
an important regulatory role in several physiologic and
pathological processes, including cell survival, prolifera-
tion, apoptosis, and tumor development [23–25]. Previ-
ous studies have shown that the expression of SPAG9
was elevated in a variety of malignancies and correlated
with tumor stage and prognosis, including HCC [4–8,
11]. At present, the role of aberrant-expressed SPAG9 in
tumor development has been partly understood, while
overexpressed SPAG9 may induce the activation of JNK
signaling leading to tumor progression [4]. However, the
underlying mechanism leading to SPAG9 overexpression
is not well known. In this study, we identified miR-141
as a negative regulator of SPAG9 in HCC tumorigenesis.
MiR-141 was involved in the miR-200 family, which
was known as a family of tumor suppressor miRNAs.
The miR-200 family, which consists of five members
(miR-200a, miR-200b, miR-200c, miR-429, and miR-
141), are involved in the inhibition of epithelial-to-
mesenchymal transition (EMT), repression of cancer
stem cells (CSCs) self-renewal and differentiation,
modulation of cell division and apoptosis, and reversal
of chemoresistance [26, 27]. According to the prediction
results of the algorithms, there are seed sequences of all
five members in the 3′-UTR of the SPAG9 gene. Thus,
we analyzed whether the miR-200 family could directly
target SPAG9 3′-UTR with dual-luciferase reporter
assay. All five members were found to suppress reporter
gene activity in HEK293T cells; among them, miR-141
and miR-200a suppressed the reporter gene activity
more significantly (Additional file 1: Figure S1A). We
then assessed whether the ectopic expression of these
five miRNAs mimicked the effects of SPAG9 interfering
in HCC cells. As expected, ectopic overexpression of
miR-200 s elicited the suppression of SPAG9 in Huh7
cells, especially miR-141 and miR-200a (Additional file 1:
Figure S1B). Furthermore, the miR-141 and miR-200a ex-
pression in HCC tissues were investigated to verify
their expression patterns with SPAG9. This analysis
revealed that 9 out of 10 HCCs (90 %) had decreased
miR-141 and increased SPAG9 expression, as compared
with corresponding non-cancerous hepatic tissues, while 7
of 10 HCCs (70 %) had reduced miR-200a expression
(Additional file 1: Figure S1C). The inverse correlation
Fig. 2 Validation of SPAG9 as the direct target of miR-141. a Wild-type (WT) and mutant (Mut) 3′-UTR of SPAG9 were cloned into a pmiR-RB-
REPORT™ vector. b Dual-luciferase activity of the wild-type (WT) and mutant (Mut) SPAG9 3′-UTR reporter constructs in the presence of miR-141
or control miRNA (miR-NC). c MiR-141 expression levels were analyzed by real time-PCR in miR-141- or control miRNA- (miR-NC) transfected LM3
and Huh7 cells. d Western blot analysis of SPAG9 expression in LM3 and Huh7 cells transfected with miR-141 mimics or control miRNA. Data are
presented as the mean ± S.D. (*P < 0.05, n = 3)
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between SPAG9 expression and miR-141 was more prom-
inent than that between SPAG9 and miR-200a. We further
expand the sample size by analyzing the expression levels
of SPAG9 and miR-141 in 24 other matched HCC and
hepatic tissues. Additional file 1: Figure S2 shows that the
SPAG9 expression was significantly inversely correlated
with the miR-141 level in these HCC tissues. Moreover,
the miRNA array analysis also presented that the expres-
sion levels of miR-200 family members, especially miR-
141, were downregulated in a high SPAG9 expression
HCC tissue or cell line as compared with low SPAG9 ex-
pression ones (Additional file 1: Figure S3). These results
suggested that miR-141 is the most likely candidate
miRNA regulating SPAG9 expression in liver
tumorigenesis.
MiR-141 is negatively regulated in different types of
cancers and is considered to be a tumor suppressor, e.g.,
ovarian cancer, breast cancer, or gastric cancer, by target-
ing a number of important genes such as p38α [28],
Stat5a [29], TAZ [30], and others [31, 32]. Moreover,
several in vivo studies have shown that the overexpres-
sion of miR-141 could suppress tumor growth and me-
tastasis in a tumor xenograft mice model [30, 33]. In
HCC, miR-141 was reported to be significantly down-
regulated in human HCC tissues compared with adja-
cent normal tissues [34], and a low miR-141 expression
was a substantial prognostic factor for the poor overall
survival in HCC patients [35]. In the present study, we
also found that the downregulation of miR-141 in HCC
and the expression patterns of SPAG9 were inversely
correlated with those of miR-141 in HCC tumor samples
and cell lines (Fig. 1). In addition, the ectopic expression
of miR-141 could decrease SPAG9 protein levels in HCC
cells by directly targeting the 3′-UTR of SPAG9 mRNA
Fig. 3 Inhibition of SPAG9 or upregulation of miR-141 reduces proliferation, migration, and invasion of HCC cells. a Western blot analysis of
SPAG9 expression in LM3 and Huh7 cells transfected with SPAG9 siRNA (si-SPAG9) or control siRNA (si-Ctrl). b MTT assay showed that the inhib-
ition of SPAG9 or ectopic expression of miR-141 could hinder Hep3B and Huh7 cell proliferation. c and d Wound-healing assay showed that
SPAG9 depletion or miR-141 upregulation decreased cell migration of Huh7 cells. e and f Matrigel invasion assay showed that SPAG9 depletion
or miR-141 upregulation decreased cell invasion of Huh7 cells. Data are presented as the mean ± S.D. (*P < 0.05, n = 3). U.T: untreated Huh7 cells
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(Fig. 2). Recently, several studies showed that miR-141
inhibited HCC growth, migration, and invasion by tar-
geting the hepatocyte nuclear factor-3β (HNF-3β) [34], T
lymphoma invasion and metastasis 1 (Tiam1) [35], and
zinc finger E-box binding homeobox 2 (ZEB2) [36]. In
the present study, we further expanded the function of
miR-141 in HCC. We found that the upregulation of
miR-141 could suppress HCC cell growth and invasion
and knockdown of SPAG9-induced effects that were
similar to those stimulated by miR-141 (Fig. 3). To fur-
ther confirm that SPAG9 is a functional target of miR-
141, we transfected miR-141 overexpressing HCC cells
with SPAG9 plasmid, which encrypted the full-length
coding sequence of SPAG9 without its 3′-UTR and
found that the overexpression of SPAG9 lacking its 3′-
UTR substantially reversed the tumor-suppressive effects
of miR-141 (Fig. 3). These results demonstrate that
SPAG9 is another functional target gene of miR-141 in
HCC, and miR-141 may also elicit a tumor-suppressing
effect via SPAG9 targeting.
Previous research demonstrated that SPAG9 was en-
gaged in JNK pathway [37], which is closely related to
tumor progression. To further provide mechanistic
insight into the role of miR-141 and SPAG9 in HCC
growth and metastasis, we examined the effect of miR-
141-mediated SPAG9 regulation on JNK activation. We
Fig. 4 MiR-141 inhibits HCC cell growth and metastasis by targeting SPAG9. a SPAG9 plasmid or control vector was transfected into miR-141-
overexpression HCC cells. MTT assay showed that the restoration of SPAG9 in miR-141-transfected cells attenuated the inhibitory effects of miR-
141 on cell proliferation, especially at 48 h and 72 h. b, c Matrigel invasion assay showed that restoration of SPAG9 reversed the inhibitory effects
of miR-141 on the invasion of Huh7 cells. d, e Wound-healing assay showed that the restoration of SPAG9 increased the migration of miR-141-
transfected Huh7 cells. Data are presented as the mean ± S.D. (*P < 0.05, n = 3). U.T: untreated HCC cells; miR-141 + Ctrl: miR-141 and control
vector co-transfected HCC cells; miR-141 + SPAG9: miR-141 and SPAG9 plasmid co-transfected HCC cells
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found that the p-JNK level was reduced by miR-141
overexpression, similar to those by SPAG9 silencing
(Fig. 5a). Moreover, the overexpression of SPAG9 lacking
it’s 3′-UTR significantly restored JNK activity in miR-
141-transfected Huh7 cells (Fig. 5b), indicating that
miR-141 activates the JNK signaling pathway via SPAG9
regulation. Since c-Jun and MMP9, which are a major
downstream molecule and a target gene in the JNK
pathway, were reported to play important roles in JNK-
mediated tumor growth and metastasis [38], we further
examined the effect of miR-141 and SPAG9 on these
gene expressions. As anticipated, the overexpression of
miR-141 significantly decreased c-Jun and MMP9 ex-
pression, while the restoration of SPAG9 expression re-
versed the effects of miR-141 on these genes (Fig. 5c
and d). Previous research also showed that SPAG9 might
act as an important promoter of tumor invasion via
the SPAG9/JNK/MMP9 pathway in lung cancer [4].
MiR-141 is reported to function as a tumor suppres-
sor and inhibit EMT and metastasis of tumor cells by
targeting ZEB2 [39, 40]. Our study also showed that
the overexpression of miR-141 could downregulate
the protein level of ZEB2 (data not shown). Thus, the
anti-metastasis effect of miR-141 via targeting the
EMT regulator ZEB2 could not be partly excluded.
However, Fig. 4 shows that the restoration of SPAG9
expression in miR-141-transfected cells significantly
reversed the inhibitory effects of miR-141 on the mi-
gration and invasion of HCC cells, indicating that the
SPAG9-JNK-MMP9 axis is also engaged in the anti-
metastasis effect of miR-141 on HCC.
Conclusions
Our results suggest that the downregulation of miR-141
may cause an aberrant overexpression of SPAG9 in hu-
man HCC. In addition, our data also expanded the func-
tion of tumor-suppressive miR-141. MiR-141-mediated
suppression of SPAG9 inhibits cell growth and metasta-
sis through the JNK signaling pathway, thereby provid-
ing novel therapeutic options for HCC.
Ethics approval and consent to participate
This study was approved by the ethics committee of
First Affiliated Hospital of Zhejiang University, and in-
formed consent was obtained from each patients.
Fig. 5 MiR-141 regulates JNK signaling pathway via SPAG9 in HCC cells. a Western blot analysis showed that SPAG9 depletion or miR-141 transfection
decreased JNK protein expression and downregulated JNK phosphorylation in Huh7 cells. b Western blot analysis showed that SPAG9 overexpression
significantly restored the expression of phosphorylated JNK in miR-141-transfected Huh7 cells. c and d Real time-PCR (c) and Western blot analysis (d)
of MMP9 and c-Jun expression in Huh7 cells transfected with miR-141 or co-transfected with miR-141 and SPAG9 plasmid. Data are presented as the
mean ± S.D. (*P < 0.05, n = 3). U.T: untreated Huh7 cells; miR-141 + Ctrl: miR-141 and control vector co-transfected Huh7 cells; miR-141 + SPAG9: miR-
141 and SPAG9 plasmid co-transfected Huh7 cells
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